Goldberg J F, Garno J L, Leon A C, Kocsis J H, Portera L
Payne Whitney Clinic, New York Hospital-Cornell University Medical College, NY 10021, USA.
J Clin Psychiatry. 1998 Apr;59(4):151-8. doi: 10.4088/jcp.v59n0402.
Recent investigations have suggested that the antimanic agents divalproex sodium and carbamazepine may each hasten hospital discharge and be especially beneficial in treating mixed-state mania. This study retrospectively compared the time to remission for pure versus mixed manic bipolar inpatients who were taking lithium, divalproex, or carbamazepine, or their combination, under naturalistic conditions.
Records were reviewed for 120 bipolar inpatients from 1991 to 1995. Research DSM-III-R diagnoses of pure or mixed mania were assigned along standardized guidelines. Data were obtained on daily symptoms, medication doses, and blood levels. Weekly improvement was evaluated by Kaplan-Meier survival analysis of Clinical Global Impressions scale scores. Variables associated with "remission" versus "nonremission" were examined by logistic regression.
Mixed mania (N = 70) was more common than pure mania (N = 50). No significant differences were observed in the time to remission for mixed or pure manic bipolar patients who took lithium compared with those who took divalproex or carbamazepine. In patients who remained symptomatic with lithium as a single-agent mood stabilizer despite therapeutic serum lithium levels, the addition of a second mood stabilizer led to rapid symptom improvement. Among all medication subgroups, the speed with which patients achieved therapeutic blood levels of any of these agents significantly affected the time to remission.
Mixed manic bipolar patients taking lithium, divalproex, or carbamazepine under naturalistic conditions remit at comparable rates. Those failing to respond to single-agent mood stabilizers often receive combinations of mood stabilizers. However, delays in optimizing a medication regimen may attenuate short-term outcome, regardless of the mood stabilizer selected. Rapid achievement of therapeutic blood levels of any antimanic agent appears to be strongly related to swift symptom remission.
近期研究表明,抗躁狂药物丙戊酸二钠和卡马西平可能均可加速出院,且在治疗混合状态躁狂方面尤其有益。本研究回顾性比较了在自然状态下服用锂盐、丙戊酸、卡马西平或其联合用药的单纯型与混合型躁狂双相情感障碍住院患者的缓解时间。
回顾了1991年至1995年期间120例双相情感障碍住院患者的病历。根据标准化指南对研究对象进行研究性DSM-III-R诊断,分为单纯型或混合型躁狂。获取每日症状、药物剂量和血药浓度的数据。通过临床总体印象量表评分的Kaplan-Meier生存分析评估每周的改善情况。通过逻辑回归分析与“缓解”和“未缓解”相关的变量。
混合型躁狂(N = 70)比单纯型躁狂(N = 50)更常见。服用锂盐的混合型或单纯型躁狂双相情感障碍患者与服用丙戊酸或卡马西平的患者相比,缓解时间无显著差异。对于尽管血清锂水平达到治疗浓度但作为单一心境稳定剂使用锂盐时仍有症状的患者,加用第二种心境稳定剂可使症状迅速改善。在所有药物亚组中,患者达到这些药物中任何一种治疗血药浓度的速度显著影响缓解时间。
在自然状态下服用锂盐、丙戊酸或卡马西平的混合型躁狂双相情感障碍患者缓解率相当。对单一心境稳定剂无反应的患者常接受心境稳定剂联合治疗。然而,无论选择何种心境稳定剂,优化药物治疗方案的延迟可能会削弱短期疗效。迅速达到任何抗躁狂药物的治疗血药浓度似乎与症状迅速缓解密切相关。